233 related articles for article (PubMed ID: 9932084)
1. [Irinotecan in combination for colon cancer].
Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
[TBL] [Abstract][Full Text] [Related]
2. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Mitry E; Ducreux M; Rougier P
Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
4. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Van Cutsem E; Peeters M
Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
10. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V
Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
12. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Cohen MS; Al-Kasspooles MF; Williamson SK; Henry D; Broward M; Roby KF
Ann Surg Oncol; 2010 Jan; 17(1):296-303. PubMed ID: 19707832
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
14. [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
Krieger G
Strahlenther Onkol; 2001 Jun; 177(6):316-8. PubMed ID: 11446323
[No Abstract] [Full Text] [Related]
15. [Standard therapy of CPT-11 for colorectal cancer].
Saitoh S; Sakata Y
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1345-51. PubMed ID: 11681240
[TBL] [Abstract][Full Text] [Related]
16. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
17. [Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer].
André T; Louvet C; Maindrault-Goebel F; Gramont AD
Bull Cancer; 2001 Aug; 88 Spec No():S20-5. PubMed ID: 11567910
[TBL] [Abstract][Full Text] [Related]
18. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
20. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
